Pentoxifylline and prevention of contrast-induced nephropathy: Is it efficient in patients with myocardial infarction undergoing coronary angioplasty?
<div><p><strong>BACKGROUND:</strong> Contrast-induced nephropathy (CIN) is a major concern following procedures with applying iodinated contrast media. The basis prevention of CIN is hydration and to avoid hypovolemia. We aimed to evaluate the efficacy of pentoxifylline (PTX)...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Vesnu Publications
2016-12-01
|
| Series: | ARYA Atherosclerosis |
| Subjects: | |
| Online Access: | http://arya.mui.ac.ir/index.php/arya/article/view/1331 |
| _version_ | 1828199025297326080 |
|---|---|
| author | Ali Eshraghi Roya Naranji-Sani Hourak Pourzand Mohammad Vojdanparast Negar Morovatfar Javad Ramezani Ramin Khamene-Bagheri Pouya Nezafati |
| author_facet | Ali Eshraghi Roya Naranji-Sani Hourak Pourzand Mohammad Vojdanparast Negar Morovatfar Javad Ramezani Ramin Khamene-Bagheri Pouya Nezafati |
| author_sort | Ali Eshraghi |
| collection | DOAJ |
| description | <div><p><strong>BACKGROUND:</strong> Contrast-induced nephropathy (CIN) is a major concern following procedures with applying iodinated contrast media. The basis prevention of CIN is hydration and to avoid hypovolemia. We aimed to evaluate the efficacy of pentoxifylline (PTX) for the prevention of CIN in patients with myocardial infarction (MI) undergoing coronary angioplasty.</p> <p><strong>METHODS:</strong> This prospective, single-blind, randomized clinical trial study was performed on <br /> 175 (127 men) of MI patients undergoing routine treatment. Patients were assigned randomly to the control (n = 84) and study groups (n = 91). In our study group, patients received 400 mg/3 times a day from 24 hours before to 24 hours after coronary angiography. In addition, before the procedure and after 48 hours from the procedure, serum creatinine was measured.</p> <p><strong>RESULTS:</strong><strong> </strong>CIN occurred in 14 patients (8.0%); 8 controls (9.5%) and 6 patients (6.6%) in the PTX group )P = 0.475) showing PTX to have no significant effect on CIN [P = 0.750, odds <br /> ratio = 0.82 (confidence interval = 0.24-2.8)] though a significantly different volume of contrast was used between the groups (231.29 ± 105.10 mm<sup>3</sup> and 190.88 ± 75.82 mm<sup>3</sup>; P = 0.005, respectively).</p> <p><strong>CONCLUSION:</strong> There was no significantly different occurrence of CIN on patients with MI, undergoing coronary angioplasty, but its relatively lower rate in PTX group would recommend the prophylactic oral use of PTX for CIN prevention.</p></div><p> </p> |
| first_indexed | 2024-04-12T10:47:00Z |
| format | Article |
| id | doaj.art-b2b1e8017d2e41ed9b4be0ea7074f4c6 |
| institution | Directory Open Access Journal |
| issn | 1735-3955 2251-6638 |
| language | English |
| last_indexed | 2024-04-12T10:47:00Z |
| publishDate | 2016-12-01 |
| publisher | Vesnu Publications |
| record_format | Article |
| series | ARYA Atherosclerosis |
| spelling | doaj.art-b2b1e8017d2e41ed9b4be0ea7074f4c62022-12-22T03:36:22ZengVesnu PublicationsARYA Atherosclerosis1735-39552251-66382016-12-01125238242614Pentoxifylline and prevention of contrast-induced nephropathy: Is it efficient in patients with myocardial infarction undergoing coronary angioplasty?Ali Eshraghi0Roya Naranji-Sani1Hourak Pourzand2Mohammad Vojdanparast3Negar Morovatfar4Javad Ramezani5Ramin Khamene-Bagheri6Pouya Nezafati7Assistant Professor, Atherosclerosis Prevention Research Center AND Department of Cardiology, Imam Reza School of Medicine, Imam Reza Hospital, Mashhad, University of Medical Sciences, Mashhad, IranResident, Department of Cardiology, Imam Reza School of Medicine, Imam Reza Hospital, Mashhad University of Medical Sciences, Mashhad, IranAssociate Professor, Atherosclerosis Prevention Research Center AND Department of Cardiology, Imam Reza School of Medicine, Imam Reza Hospital, Mashhad, University of Medical Sciences, Mashhad, IranCardiologist, Atherosclerosis Prevention Research Center, Imam Reza Hospital, Mashhad University of Medical Sciences, Mashhad, IranAssistant Professor, Imam Reza Clinical Research Units, School of Medicine, Mashhad University of Medical Sciences, Mashhad, IranAssistant Professor, Atherosclerosis Prevention Research Center AND Department of Cardiology, Imam Reza School of Medicine, Imam Reza Hospital, Mashhad, University of Medical Sciences, Mashhad, IranAssistant Professor, Atherosclerosis Prevention Research Center AND Department of Cardiology, Imam Reza School of Medicine, Imam Reza Hospital, Mashhad, University of Medical Sciences, Mashhad, IranGeneral Practitioner, Cardiac Rehabilitation Research Center, Cardiovascular Research Institute, Isfahan University of Medicine Sciences, Isfahan, Iran<div><p><strong>BACKGROUND:</strong> Contrast-induced nephropathy (CIN) is a major concern following procedures with applying iodinated contrast media. The basis prevention of CIN is hydration and to avoid hypovolemia. We aimed to evaluate the efficacy of pentoxifylline (PTX) for the prevention of CIN in patients with myocardial infarction (MI) undergoing coronary angioplasty.</p> <p><strong>METHODS:</strong> This prospective, single-blind, randomized clinical trial study was performed on <br /> 175 (127 men) of MI patients undergoing routine treatment. Patients were assigned randomly to the control (n = 84) and study groups (n = 91). In our study group, patients received 400 mg/3 times a day from 24 hours before to 24 hours after coronary angiography. In addition, before the procedure and after 48 hours from the procedure, serum creatinine was measured.</p> <p><strong>RESULTS:</strong><strong> </strong>CIN occurred in 14 patients (8.0%); 8 controls (9.5%) and 6 patients (6.6%) in the PTX group )P = 0.475) showing PTX to have no significant effect on CIN [P = 0.750, odds <br /> ratio = 0.82 (confidence interval = 0.24-2.8)] though a significantly different volume of contrast was used between the groups (231.29 ± 105.10 mm<sup>3</sup> and 190.88 ± 75.82 mm<sup>3</sup>; P = 0.005, respectively).</p> <p><strong>CONCLUSION:</strong> There was no significantly different occurrence of CIN on patients with MI, undergoing coronary angioplasty, but its relatively lower rate in PTX group would recommend the prophylactic oral use of PTX for CIN prevention.</p></div><p> </p>http://arya.mui.ac.ir/index.php/arya/article/view/1331PentoxifyllineMyocardial InfarctionContrast MediaAngioplastyNephropathyCreatinine |
| spellingShingle | Ali Eshraghi Roya Naranji-Sani Hourak Pourzand Mohammad Vojdanparast Negar Morovatfar Javad Ramezani Ramin Khamene-Bagheri Pouya Nezafati Pentoxifylline and prevention of contrast-induced nephropathy: Is it efficient in patients with myocardial infarction undergoing coronary angioplasty? ARYA Atherosclerosis Pentoxifylline Myocardial Infarction Contrast Media Angioplasty Nephropathy Creatinine |
| title | Pentoxifylline and prevention of contrast-induced nephropathy: Is it efficient in patients with myocardial infarction undergoing coronary angioplasty? |
| title_full | Pentoxifylline and prevention of contrast-induced nephropathy: Is it efficient in patients with myocardial infarction undergoing coronary angioplasty? |
| title_fullStr | Pentoxifylline and prevention of contrast-induced nephropathy: Is it efficient in patients with myocardial infarction undergoing coronary angioplasty? |
| title_full_unstemmed | Pentoxifylline and prevention of contrast-induced nephropathy: Is it efficient in patients with myocardial infarction undergoing coronary angioplasty? |
| title_short | Pentoxifylline and prevention of contrast-induced nephropathy: Is it efficient in patients with myocardial infarction undergoing coronary angioplasty? |
| title_sort | pentoxifylline and prevention of contrast induced nephropathy is it efficient in patients with myocardial infarction undergoing coronary angioplasty |
| topic | Pentoxifylline Myocardial Infarction Contrast Media Angioplasty Nephropathy Creatinine |
| url | http://arya.mui.ac.ir/index.php/arya/article/view/1331 |
| work_keys_str_mv | AT alieshraghi pentoxifyllineandpreventionofcontrastinducednephropathyisitefficientinpatientswithmyocardialinfarctionundergoingcoronaryangioplasty AT royanaranjisani pentoxifyllineandpreventionofcontrastinducednephropathyisitefficientinpatientswithmyocardialinfarctionundergoingcoronaryangioplasty AT hourakpourzand pentoxifyllineandpreventionofcontrastinducednephropathyisitefficientinpatientswithmyocardialinfarctionundergoingcoronaryangioplasty AT mohammadvojdanparast pentoxifyllineandpreventionofcontrastinducednephropathyisitefficientinpatientswithmyocardialinfarctionundergoingcoronaryangioplasty AT negarmorovatfar pentoxifyllineandpreventionofcontrastinducednephropathyisitefficientinpatientswithmyocardialinfarctionundergoingcoronaryangioplasty AT javadramezani pentoxifyllineandpreventionofcontrastinducednephropathyisitefficientinpatientswithmyocardialinfarctionundergoingcoronaryangioplasty AT raminkhamenebagheri pentoxifyllineandpreventionofcontrastinducednephropathyisitefficientinpatientswithmyocardialinfarctionundergoingcoronaryangioplasty AT pouyanezafati pentoxifyllineandpreventionofcontrastinducednephropathyisitefficientinpatientswithmyocardialinfarctionundergoingcoronaryangioplasty |